Literature DB >> 26574643

Theophylline Represses IL-8 Secretion from Airway Smooth Muscle Cells Independently of Phosphodiesterase Inhibition. Novel Role as a Protein Phosphatase 2A Activator.

Brijeshkumar S Patel1, Md Mostafizur Rahman1, Nowshin N Rumzhum1, Brian G Oliver2,3, Nicole M Verrills4, Alaina J Ammit1.   

Abstract

Theophylline is an old drug experiencing a renaissance owing to its beneficial antiinflammatory effects in chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease. Multiple modes of antiinflammatory action have been reported, including inhibition of the enzymes that degrade cAMP-phosphodiesterase (PDE). Using primary cultures of airway smooth muscle (ASM) cells, we recently revealed that PDE4 inhibitors can potentiate the antiinflammatory action of β2-agonists by augmenting cAMP-dependent expression of the phosphatase that deactivates mitogen-activated protein kinase (MAPK)-MAPK phosphatase (MKP)-1. Therefore, the aim of this study was to address whether theophylline repressed cytokine production in a similar, PDE-dependent, MKP-1-mediated manner. Notably, theophylline did not potentiate cAMP release from ASM cells treated with the long-acting β2-agonist formoterol. Moreover, theophylline (0.1-10 μM) did not increase formoterol-induced MKP-1 messenger RNA expression nor protein up-regulation, consistent with the lack of cAMP generation. However, theophylline (at 10 μM) was antiinflammatory and repressed secretion of the neutrophil chemoattractant cytokine IL-8, which is produced in response to TNF-α. Because theophylline's effects were independent of PDE4 inhibition or antiinflammatory MKP-1, we then wished to elucidate the novel mechanisms responsible. We investigated the impact of theophylline on protein phosphatase (PP) 2A, a master controller of multiple inflammatory signaling pathways, and show that theophylline increases TNF-α-induced PP2A activity in ASM cells. Confirmatory results were obtained in A549 lung epithelial cells. PP2A activators have beneficial effects in ex vivo and in vivo models of respiratory disease. Thus, our study is the first to link theophylline with PP2A activation as a novel mechanism to control respiratory inflammation.

Entities:  

Keywords:  IL-8; airway smooth muscle; cAMP; phosphodiesterase; protein phosphatase 2A

Mesh:

Substances:

Year:  2016        PMID: 26574643     DOI: 10.1165/rcmb.2015-0308OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  5 in total

1.  The phosphorylated form of FTY720 activates PP2A, represses inflammation and is devoid of S1P agonism in A549 lung epithelial cells.

Authors:  Md Mostafizur Rahman; Laura Prünte; Leonard F Lebender; Brijeshkumar S Patel; Ingrid Gelissen; Philip M Hansbro; Jonathan C Morris; Andrew R Clark; Nicole M Verrills; Alaina J Ammit
Journal:  Sci Rep       Date:  2016-11-16       Impact factor: 4.379

2.  Extracellular acidification-induced CXCL8 production through a proton-sensing receptor OGR1 in human airway smooth muscle cells: a response inhibited by dexamethasone.

Authors:  Maiko Kadowaki; Hidenori Yamada; Koichi Sato; Hiroko Shigemi; Yukihiro Umeda; Miwa Morikawa; Yuko Waseda; Masaki Anzai; Yosuke Kamide; Haruka Aoki-Saito; Takeshi Hisada; Fumikazu Okajima; Tamotsu Ishizuka
Journal:  J Inflamm (Lond)       Date:  2019-02-19       Impact factor: 4.981

Review 3.  Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration.

Authors:  Andrew R Clark; Michael Ohlmeyer
Journal:  Pharmacol Ther       Date:  2019-06-01       Impact factor: 12.310

Review 4.  Post-tuberculous lung disease: should we be using Theophylline?

Authors:  Sumanth Karamchand; Morne Williams; Poobalan Naidoo; Eric Decloedt; Brian Allwood
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

Review 5.  Theophylline: Old Drug in a New Light, Application in COVID-19 through Computational Studies.

Authors:  Luis M Montaño; Bettina Sommer; Juan C Gomez-Verjan; Genaro S Morales-Paoli; Gema Lizbeth Ramírez-Salinas; Héctor Solís-Chagoyán; Zuly A Sanchez-Florentino; Eduardo Calixto; Gloria E Pérez-Figueroa; Rohan Carter; Ruth Jaimez-Melgoza; Bianca S Romero-Martínez; Edgar Flores-Soto
Journal:  Int J Mol Sci       Date:  2022-04-09       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.